A detailed history of Capstone Investment Advisors, LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Capstone Investment Advisors, LLC holds 13,951 shares of AUTL stock, worth $41,713. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,951
Holding current value
$41,713
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.38 - $4.69 $47,154 - $65,430
13,951 New
13,951 $50,000
Q1 2024

May 01, 2024

BUY
$5.39 - $7.29 $158,325 - $214,136
29,374 Added 58.75%
79,374 $506,000
Q4 2023

Feb 12, 2024

BUY
$2.13 - $6.63 $106,500 - $331,500
50,000 New
50,000 $322,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Capstone Investment Advisors, LLC Portfolio

Follow Capstone Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.